BackReunion Neuroscience Overview

Reunion Neuroscience Total Liabilities

Track Reunion Neuroscience's total liabilities ($8.4M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$8.44M
75.99% YoYΔ $-26.73M vs prior year quarter

Peer average

Loading

Reunion Neuroscience Total Liabilities History

Loading

Reunion Neuroscience vs. peers: Total Liabilities Comparison

Loading

Reunion Neuroscience Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Reunion Neuroscience (REUN) FAQ

Reunion Neuroscience posts a total liabilities of $8.4M as of March 2023. That compares with $35M in the prior-year period — down 76.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Reunion Neuroscience's total liabilities was $35M. The latest reading is $8.4M — a 76.0% year-over-year decrease (period ending March 2023). Use the history and growth charts on this page for a longer lookback.

Total Liabilities is one piece of Reunion Neuroscience's financial statement story. At $8.4M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for REUN's total liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Reunion Neuroscience's other metric pages and overview cover the third.

Judging Reunion Neuroscience against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in total liabilities easier to interpret. Start with $8.4M here, then scan peer and history charts to see if the gap is persistent.